Q32 BIO INC (QTTB) Stock Price, Quote, News and Overview
NASDAQ:QTTB - Nasdaq - US7469641051 - Common Stock - Currency: USD
QTTB Quote, Performance and Key Statistics
2.57
+0.14 (+5.76%)
The current stock price of QTTB is 2.57 USD. In the past month the price decreased by -23.74%.
QTTB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About QTTB
Company Profile
Q32 Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 42 full-time employees. The company went IPO on 2018-03-28. Q32 Bio Inc. is a clinical-stage biotechnology company. The firm is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. The company is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The firm has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
Company Info
Q32 BIO INC
830 Winter Street
Waltham MASSACHUSETTS US
Employees: 42
Company Website: https://www.q32bio.com/
Investor Relations: https://investors.homologymedicines.com/
Phone: 17819990232
Q32 BIO INC / QTTB FAQ
What is the stock price of Q32 BIO INC today?
The current stock price of QTTB is 2.57 USD. The price increased by 5.76% in the last trading session.
What is the ticker symbol for Q32 BIO INC stock?
The exchange symbol of Q32 BIO INC is QTTB and it is listed on the Nasdaq exchange.
On which exchange is QTTB stock listed?
QTTB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Q32 BIO INC stock?
11 analysts have analysed QTTB and the average price target is 10 USD. This implies a price increase of 288.95% is expected in the next year compared to the current price of 2.57. Check the Q32 BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Q32 BIO INC worth?
Q32 BIO INC (QTTB) has a market capitalization of 31.30M USD. This makes QTTB a Nano Cap stock.
How many employees does Q32 BIO INC have?
Q32 BIO INC (QTTB) currently has 42 employees.
What are the support and resistance levels for Q32 BIO INC (QTTB) stock?
Q32 BIO INC (QTTB) has a resistance level at 3.07. Check the full technical report for a detailed analysis of QTTB support and resistance levels.
Is Q32 BIO INC (QTTB) expected to grow?
The Revenue of Q32 BIO INC (QTTB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the QTTB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Q32 BIO INC (QTTB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QTTB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QTTB, evaluating the profitability, health, valuation and growth aspects
- Q32 BIO INC (QTTB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Q32 BIO INC (QTTB) Sales and EPS estimates to see what analysts future expectations are.
- Q32 BIO INC (QTTB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Q32 BIO INC (QTTB) Insider and Institutional Ownership to learn about the owners and their transactions.
- Q32 BIO INC (QTTB) Stock Chart to make your own analysis
- Q32 BIO INC (QTTB) Latest news and press-releases to stay up to date.
Does Q32 BIO INC (QTTB) stock pay dividends?
QTTB does not pay a dividend.
When does Q32 BIO INC (QTTB) report earnings?
Q32 BIO INC (QTTB) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of Q32 BIO INC (QTTB)?
Q32 BIO INC (QTTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.87).
What is the Short Interest ratio of Q32 BIO INC (QTTB) stock?
The outstanding short interest for Q32 BIO INC (QTTB) is 14.72% of its float. Check the ownership tab for more information on the QTTB short interest.
QTTB Technical Analysis
QTTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to QTTB. While QTTB seems to be doing ok healthwise, there are quite some concerns on its profitability.
QTTB Financial Highlights
Over the last trailing twelve months QTTB reported a non-GAAP Earnings per Share(EPS) of -22.87. The EPS decreased by -2.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.51% | ||
| ROE | -271.46% | ||
| Debt/Equity | 0.61 |
QTTB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to QTTB. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 78.62% and a revenue growth -100% for QTTB